The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis

H. A. Chen, K. C. Lin, C. H. Chen, H. T. Liao, H. P. Wang, H. N. Chang, C. Y. Tsai, Chung Tei Chou

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Objective: To evaluate the changes in anti-cyclic citrullinated peptide antibodies (anti-CCP) and rheumatoid factor (RF) following etanercept treatment in patients with rheumatoid arthritis. Methods: The study included 90 patients with rheumatoid arthritis who failed treatment with disease modifying antirheumatic drugs (DMARDs). All patients were allowed to continue treatment with DMARDs; 52 of them received etanercept as a twice weekly 25 mg subcutaneous injection for three months, and the others did not. Serum samples were collected at baseline and one month intervals during the treatment course. The serum levels of anti-CCP and RF were tested by enzyme linked immunosorbent assay and nephelometry, respectively. Results: At baseline, 45 of the 52 etanercept treated patients (86.5%) and 32 of the 38 controls (84.2%) were positive for anti-CCP. Tests for RF were positive in 78.9% and 84.2% of patients with or without etanercept treatment, respectively. The serum levels of anti-CCP and RF decreased significantly after a three month etanercept treatment (p = 0.007 and p = 0.006, respectively). The average decrease from baseline calculated for each individual patient in the etanercept treated group was 31.3% for anti-CCP and 36% for RF. The variation in anti-CCP was positively correlated with the variation in disease activity, swollen and tender joint counts, RF, and C reactive protein. Conclusions: Etanercept combined with DMARDs leads to a much greater decrease than DMARDs alone in the serum levels of anti-CCP and RF in rheumatoid arthritis, compatible with a reduction in clinical disease activity.

Original languageEnglish
Pages (from-to)35-39
Number of pages5
JournalAnnals of the Rheumatic Diseases
Volume65
Issue number1
DOIs
Publication statusPublished - Jan 2006
Externally publishedYes

Fingerprint

Rheumatoid Factor
Rheumatoid Arthritis
Antirheumatic Agents
Antibodies
Serum
Therapeutics
Nephelometry and Turbidimetry
Immunosorbents
Subcutaneous Injections
Etanercept
cyclic citrullinated peptide
C-Reactive Protein
Assays
Joints
Enzyme-Linked Immunosorbent Assay
Enzymes

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. / Chen, H. A.; Lin, K. C.; Chen, C. H.; Liao, H. T.; Wang, H. P.; Chang, H. N.; Tsai, C. Y.; Chou, Chung Tei.

In: Annals of the Rheumatic Diseases, Vol. 65, No. 1, 01.2006, p. 35-39.

Research output: Contribution to journalArticle

Chen, H. A. ; Lin, K. C. ; Chen, C. H. ; Liao, H. T. ; Wang, H. P. ; Chang, H. N. ; Tsai, C. Y. ; Chou, Chung Tei. / The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. In: Annals of the Rheumatic Diseases. 2006 ; Vol. 65, No. 1. pp. 35-39.
@article{0e782016f4df4dbf90a1ab7b051d2b94,
title = "The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis",
abstract = "Objective: To evaluate the changes in anti-cyclic citrullinated peptide antibodies (anti-CCP) and rheumatoid factor (RF) following etanercept treatment in patients with rheumatoid arthritis. Methods: The study included 90 patients with rheumatoid arthritis who failed treatment with disease modifying antirheumatic drugs (DMARDs). All patients were allowed to continue treatment with DMARDs; 52 of them received etanercept as a twice weekly 25 mg subcutaneous injection for three months, and the others did not. Serum samples were collected at baseline and one month intervals during the treatment course. The serum levels of anti-CCP and RF were tested by enzyme linked immunosorbent assay and nephelometry, respectively. Results: At baseline, 45 of the 52 etanercept treated patients (86.5{\%}) and 32 of the 38 controls (84.2{\%}) were positive for anti-CCP. Tests for RF were positive in 78.9{\%} and 84.2{\%} of patients with or without etanercept treatment, respectively. The serum levels of anti-CCP and RF decreased significantly after a three month etanercept treatment (p = 0.007 and p = 0.006, respectively). The average decrease from baseline calculated for each individual patient in the etanercept treated group was 31.3{\%} for anti-CCP and 36{\%} for RF. The variation in anti-CCP was positively correlated with the variation in disease activity, swollen and tender joint counts, RF, and C reactive protein. Conclusions: Etanercept combined with DMARDs leads to a much greater decrease than DMARDs alone in the serum levels of anti-CCP and RF in rheumatoid arthritis, compatible with a reduction in clinical disease activity.",
author = "Chen, {H. A.} and Lin, {K. C.} and Chen, {C. H.} and Liao, {H. T.} and Wang, {H. P.} and Chang, {H. N.} and Tsai, {C. Y.} and Chou, {Chung Tei}",
year = "2006",
month = "1",
doi = "10.1136/ard.2005.038851",
language = "English",
volume = "65",
pages = "35--39",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis

AU - Chen, H. A.

AU - Lin, K. C.

AU - Chen, C. H.

AU - Liao, H. T.

AU - Wang, H. P.

AU - Chang, H. N.

AU - Tsai, C. Y.

AU - Chou, Chung Tei

PY - 2006/1

Y1 - 2006/1

N2 - Objective: To evaluate the changes in anti-cyclic citrullinated peptide antibodies (anti-CCP) and rheumatoid factor (RF) following etanercept treatment in patients with rheumatoid arthritis. Methods: The study included 90 patients with rheumatoid arthritis who failed treatment with disease modifying antirheumatic drugs (DMARDs). All patients were allowed to continue treatment with DMARDs; 52 of them received etanercept as a twice weekly 25 mg subcutaneous injection for three months, and the others did not. Serum samples were collected at baseline and one month intervals during the treatment course. The serum levels of anti-CCP and RF were tested by enzyme linked immunosorbent assay and nephelometry, respectively. Results: At baseline, 45 of the 52 etanercept treated patients (86.5%) and 32 of the 38 controls (84.2%) were positive for anti-CCP. Tests for RF were positive in 78.9% and 84.2% of patients with or without etanercept treatment, respectively. The serum levels of anti-CCP and RF decreased significantly after a three month etanercept treatment (p = 0.007 and p = 0.006, respectively). The average decrease from baseline calculated for each individual patient in the etanercept treated group was 31.3% for anti-CCP and 36% for RF. The variation in anti-CCP was positively correlated with the variation in disease activity, swollen and tender joint counts, RF, and C reactive protein. Conclusions: Etanercept combined with DMARDs leads to a much greater decrease than DMARDs alone in the serum levels of anti-CCP and RF in rheumatoid arthritis, compatible with a reduction in clinical disease activity.

AB - Objective: To evaluate the changes in anti-cyclic citrullinated peptide antibodies (anti-CCP) and rheumatoid factor (RF) following etanercept treatment in patients with rheumatoid arthritis. Methods: The study included 90 patients with rheumatoid arthritis who failed treatment with disease modifying antirheumatic drugs (DMARDs). All patients were allowed to continue treatment with DMARDs; 52 of them received etanercept as a twice weekly 25 mg subcutaneous injection for three months, and the others did not. Serum samples were collected at baseline and one month intervals during the treatment course. The serum levels of anti-CCP and RF were tested by enzyme linked immunosorbent assay and nephelometry, respectively. Results: At baseline, 45 of the 52 etanercept treated patients (86.5%) and 32 of the 38 controls (84.2%) were positive for anti-CCP. Tests for RF were positive in 78.9% and 84.2% of patients with or without etanercept treatment, respectively. The serum levels of anti-CCP and RF decreased significantly after a three month etanercept treatment (p = 0.007 and p = 0.006, respectively). The average decrease from baseline calculated for each individual patient in the etanercept treated group was 31.3% for anti-CCP and 36% for RF. The variation in anti-CCP was positively correlated with the variation in disease activity, swollen and tender joint counts, RF, and C reactive protein. Conclusions: Etanercept combined with DMARDs leads to a much greater decrease than DMARDs alone in the serum levels of anti-CCP and RF in rheumatoid arthritis, compatible with a reduction in clinical disease activity.

UR - http://www.scopus.com/inward/record.url?scp=29144519684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144519684&partnerID=8YFLogxK

U2 - 10.1136/ard.2005.038851

DO - 10.1136/ard.2005.038851

M3 - Article

VL - 65

SP - 35

EP - 39

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 1

ER -